Ignyta Investor Information

Ignyta, Inc. is writing a new story for cancer treatment, a story that features our distinctive Rx/Dx strategy to blaze a new path forward for patients.

Physicians discussing a patient chart

Our integrated approach combines precision therapeutics with companion molecular diagnostics for the potential benefit of patients with cancer.

Our people work daily to develop meaningful new drugs that target the molecular abnormalities of cancer, allowing us to advance precision therapies to treat each patient’s specific cancer.

We endeavor to eradicate residual disease in precisely defined patient populations by 2030, an audacious goal – backed by the unique combination of delivering the next generation of targeted therapeutics, accompanied by highly informative biomarkers for patient selection, treatment, and monitoring – that makes us confident we can help write the next chapter in the ever-changing story of cancer care.

To stay up to date on all Ignyta investor information, including Press Releases, Stock Information, SEC filings, and more, sign up for Ignyta email alerts.

Ignyta, Inc. (Nasdaq: RXDX) stock information, including a current stock ticker and historical trending.

View Stock Info

A sortable database of downloadable Ignyta, Inc. Press Releases from 2012 to present in PDF format.

Read Press Releases

A sortable database of Ignyta, Inc. SEC filings for all years 2013 to present, in HTML, PDF, and XLS formats.

View SEC Filings

Ignyta Events & Presentations

As a leader in biotechnology and precision medicine, the Ignyta team frequently presents at industry conferences and events, including clinical data, information on Ignyta clinical trials, and breakthroughs in the evolution of cancer treatment.

View Upcoming Events
Speaker in front of large group of people

Stock Information

Table scrolls to the right >>

current stock price
4 PM ET | Jan 19, 2018
Previous Close 26.85 Day High 26.95
Open 26.85 Day Low 26.80
Volume 5,143,885 52-Week High 27.10
Exchange NASDAQ 52-Week Low 4.60

Press Releases

Jan 04, 2018 Ignyta to Present at 36th Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 36th Annual J.P. Morgan Healthc
Dec 29, 2017 Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for RXDX-106,
Dec 22, 2017 Roche and Ignyta Reach Definitive Merger Agreement
Roche to acquire Ignyta for US$ 27.00 per share Ignyta's investigational medicine entrectinib, a selective CNS-active tyrosine-kinase inhibitor being developed for tumours that harbor ROS1 or NTRK fusions, to expand Roche's portfolio of oncology me